Furthermore, brexucabtagene autoleucel (KTE-X19), another CD3ζ/CD28-based CD19-specific CAR-T cell, is specified for mantle cell lymphoma (MCL) therapy. This evidence concerns the gene CD247 and mantle cell lymphoma.